- Arcutis Appoints David Topper as Chief Financial Officer
- Arcutis Promotes Todd Tucker to Chief Human Resources Officer
- Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
- New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
- Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
- Arcutis Announces Pricing of $150 Million Public Offering
- Arcutis Announces Proposed Public Offering
- Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
- Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
More ▼
Key statistics
As of last trade Arcutis Biotherapeutics Inc (ARQT:NSQ) traded at 8.75, -42.50% below its 52-week high of 15.21, set on May 04, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.36 |
---|---|
High | 9.46 |
Low | 8.73 |
Bid | 8.74 |
Offer | 8.75 |
Previous close | 9.45 |
Average volume | 3.18m |
---|---|
Shares outstanding | 114.95m |
Free float | 112.08m |
P/E (TTM) | -- |
Market cap | 1.09bn USD |
EPS (TTM) | -3.90 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 18:50 BST.
More ▼